Cost-effectiveness of treating hypertension, hyperglycemia, and hyperlipidemia in African Americans and the general population with type 2 diabetes

Journal of Health Care for the Poor and Underserved

Volumn 21, Issue 1, 2010, Pages 161-176

  Tasosa, Joseph ^a   Schuster, Richard ^b   McAlearney, John S ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c WRIGHT STATE UNIVERSITY   (United States)

Author keywords

African Americans; Cardiovascular disease; Cost effectiveness; Diabetes; Health disparities

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; ETHNOLOGY; HEALTH CARE COST; HEALTH CARE DISPARITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HEALTHCARE DISPARITIES; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 77249172733     PISSN: 10492089     EISSN: None     Source Type: Journal    
DOI: 10.1353/hpu.0.0258     Document Type: Article

References (79)

1. Narayan KM, Gregg EW, Fagot-Campagna A, et al. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract. 2000 Oct;50(Suppl 2):S77-84.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1998 Sep;21(9):1414-1431
3. Saudek CD. Progress and promise of diabetes research. JAMA. 2002 May 15;287(19): 2582-2584
4. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002 May;287(19):2542-2551
5. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003 Mar;26(3):917-932
6. Garber AJ. Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes Obes Metab. 2002 Jan;4 Suppl 1:S5-12.
7. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003 Aug 20;290(7):898-904.
8. Ingelsson E, Sundström J, Arnlöv J, et al. Insulin resistance and risk of congestive heart failure. JAMA. 2005 Jul 20;294(3):334-341 (Pubitemid 41043777)
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-359
10. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006 Jun;29(6):1263-1268
11. Smedley BD, Stith AY, Nelson AR, eds. Unequal treatment: confronting racial and ethnic disparities in health. Washington, DC: Committee on Understanding and Eliminating Racial Disparities in Health Care, Board on Health Sciences Policy, Institute of Medicine, 2003.
12. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004 Dec;53 Suppl 3:S39-47.
13. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-393 (Pubitemid 36159355)
14. United Kingdom Prospective Diabetes Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998 Sep 12;317(7160):703-713
15. Ménard J, Payette H, Baillargeon JP, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ. 2005 Dec 6;173(12):1457-1466
16. Jacobson TA, Schein JR, Williamson A, et al. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998 Oct 12;158(18):1977-1989
17. The CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998 Nov 25;280(20):1757-1763
18. Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a costeffectiveness analysis. Ann Intern Med. 2004 May 4;140(9):689-699
19. Elliott WJ, Wier DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 2000 May 8;160(9):1277-1283
20. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002 May 15;287(19):2519-2527
21. Marshall MC Jr. Diabetes in African Americans. Postgrad Med J. 2005 Dec;81(962): 734-740
22. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes (2nd ed.). New York: Oxford University Press, 2000.
23. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993 Oct-Dec;13(4):322-338
24. Egede LE, Zheng D. Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med. 2002 Feb 25;162(4):427-433
25. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):316-320
26. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-2572
27. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureasor insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-853
28. Gold MR, Siegel JE, Russell LB, et al., eds. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996.
29. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994; NHANES III household adult data files (CD-ROM). Public use data file documentation no. 76200. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
30. American Diabetes Association. Diabetes 1997 vital statistics. Alexandria, VA: American Diabetes Association, 1997.
31. Shin AY, Porter PJ, Wallace MC, et al. Quality of life of stroke in younger individuals. Utility assessment in patients with arteriovenous malformations. Stroke. 1997 Dec; 28(12):2395-2399
32. Wolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke. 1992 Nov;23(11):1551-1555
33. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993 Apr-Jun;13(2):161-165
34. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996 Nov 6;276(17):1409-1415
35. Rizzo JA, Pashko S, Friedkin R, et al. Linking the health utilities index to National Medical Expenditure Survey data. Phamacoeconomics. 1998 May;13(5 Pt 1):531-541
36. Havranek EP, McGovern KM, Weinberger J, et al. Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. J Card Fail. 1999 Jun;5(2):85-91.
37. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke. 2001 Apr;32(4):964-972
38. Nicholson T, McGuire A, Milne R. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc Disord. 2001; 1:2.
39. Nichol G, Hallstrom AP, Ornato JP, et al. Potential cost-effectiveness of public access defibrillation in the United States. Circulation. 1998 Apr 7;97(13):1315-1320
40. Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med. 1999 May 18;130(10):810-820
41. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy. 1998 Jun;44(3):215-232
42. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 1999 Jun;94(6):1593-1600
43. Anderson AN, Moodley I, Kropman K. A South African pharmaco-economic analysis of the Acute Infarction Ramipril Efficacy (AIRE) Study. Cardiovasc J S Afr. 2000 Apr;11(2):89-94.
44. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998 Apr;50(4):883-890
45. Jorgensen HS, Nakayama H, Raaschou HO, et al. Acute stroke: prognosis and a prediction of the effect of medical treatment on outcome and health care utilization. The Copenhagen Stroke Study. Neurology. 1997 Nov;49(5):1335-1342
46. American Heart Association. 1999 heart and stroke facts, statistical update. Dallas, TX: American Heart Association, 1999. Available at: downloadable/heart/1240250946756LS-1982%20Heart%20and%20Stroke%20Update042009. pdf.
47. Williams GR. Incidence and characteristics of total stroke in the United States. BMC Neurol. 2001 Dec 18;1:2.
48. Volmink JA, Newton JN, Hicks NR, et al. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. Heart. 1998 Jul;80(1):40-44
49. U.S. Renal Data System. 2004 USRDS annual data report. Medicare payments ($) per patient year at risk: all patients. Table K.4. Minneapolis, MN: U.S. Renal Data System. Available at: http://www.usrds.org/2004/ref/K-tables-04. pdf.
50. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004 Jul 21;292(3):344-350
51. Hellermann JP, Goraya TY, Jacobsen SJ, et al. Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol. Jun 15;157(12):1101-1107
52. Lauria G, Gentile M, Fassetta G, et al. Incidence and prognosis of stoke in the Belluno province, Italy. First-year results of a community-based study. Stroke. 1995 Oct; 26(10):1787-1793
53. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999 Nov 2;131(9):660-667
54. Ford ES, DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes: findings from the National Health and Nutriton Examination Survey I Epidemiologic Follow-up Study. Am J Epidemiol. 1991 Jun 15;133(12):1220-1230
55. U.S. Census Bureau, Washington DC: U.S. Census Bureau, Available at, U.S. Census Bureau. Vital statistics: life expectancy. Washington, DC: U.S. Census Bureau, 1996. Available at: http://www.census.gov/prod/2/gen/96statab/vitlstat. pdf.
56. Centers for Disease Control and Prevention. Health, United States, 2004: with chartbook on trends in the health of Americans. Hyattsville, MD: National Center for Health Statistics, 2004. Available at: http://www.cdc.gov/nchs/data/ hus/hus04.pdf.
57. Centers for Disease Control and Prevention. Death rates for 113 selected causes, alcohol-induced causes, drug-induced causes and injury by firearms, by 5-year age groups, race and sex, United States, 2002. Atlanta, GA: CDC, 2002. Available at: http://www.cdc.gov/nchs/data/dvs/mortfinal2002-work210r.pdf .
58. Zayats T. Social Security Disability Insurance Program worker experience. Actuarial Study no. 114. Table 7A and 7B. U.S. Social Security Agency, 1999. Available at: http://www.ssa.gov/OACT/NOTES/AS114/as114Tbls-7AB.html#pgfId- 1135373.
59. Waldrop J, Stern SM. U.S. Census 2004. Percentage of the civilian non-institutionalized population with any disability by age and selected race and Hispanic origin groups: 2000. Table 2. U.S. Census Bureau, Mar 2003. Available at: http://www.census.gov/prod/2003pubs/c2kbr-17.pdf.
60. Rønning OM, Guldvog B. Stroke units versus general medical wards, I: twelve- and eighteen- month survival: a randomized, controlled trial. Stroke. 1998 Jan;29(1): 58-62. (Pubitemid 28046942)
61. Veterans Affairs/Veteran Health Administration. The pharmacologic managemeny of chronic heart failure. Washington, DC: VA/VHA, 2002 Dec. Available at: http://www.pbm.va.gov/guidelines/28766chronicheartfailure.pdf.
62. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 1998 Sep 12;317(7160):713-720
63. Medical Economics Company, Inc. Red book. Montvale, NJ: Medical Economics Company, Inc., 1997.
64. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke. 1996 Sep;27(9):1459-1466
65. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997 Aug 19;96(4):1089-1096
66. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991 Mar;121(3 Pt 1):951-957
67. U.S. Renal Data System. Reference section K: economic costs of ESRD; table K.4: medicare payments per patient year at risk (YAR): all patients, 1998-2002. Minneapolis, MN: United States Renal Data System, 2004. Available at: http://www.usrdsorg/2004/ref/K-tables-04.pdf.
68. U.S. Department of Veterans Affairs. Fact sheets, programs and issues. Washington, DC: U.S. Department of Veteran Affairs, 2005.
69. Young DS, Sachais BS, Jefferies LC. Effect of disease complications on hospital costs. Clin Chem. 2002 Jan;48(1):140-149
70. Geronimus AT, Bound J, Waidmann TA, et al. Excess mortality among blacks and whites in the United States. N Engl J Med. 1996 Nov 21;335(21):1552-1558
71. Pappas G, Queen S, Hadden W, et al. The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med. 1993 Jul 8;329(2):103-109
72. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in medicare managed care. JAMA. 2002 Mar 13;287(10):1288-1294
73. Regenauer A. Prognostic aspects of metabolic syndrome. Is the "good living" syndrome regarded seriously enough in general insurance medicine practice? Versicherungsmedizin. 1996 Oct 1;48(5):161-169
74. U.S. Preventive Services Task Force. Guide to clinical preventive services (2nd ed.). Washington, DC: Office of Disease Prevention and Health Promotion, 1996.
75. Yu W, Ravelo A, Wagner TH, et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev. 2003 Sep;60(3 Suppl):146S-167S.
76. Perreault S, Hamilton VH, Lavoie F, et al. Treating hyperlipidemia for the primary prevention of coronary disease: Are higher dosages of lovastatin cost-effective? Arch Intern Med. 1998 Feb 23;158(4):375-381
77. Gibson RC. The age-by-race gap in health and mortality in the older population: a social science research agenda. Gerontologist. 1994 Aug;34(4):454-462
78. Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primar and secondary prevention of coronary artery disease. Pharmacoeconomics. 1999 Jan; 15(1):47-74.
79. U.S. Department of Health and Human Services. Healthy people 2010. Rockville, MD: U.S. Department of Health and Human Services, 2009. Available at: http://www.healthypeople.gov/Publications/.